[The use of prostatilen in treating patients with chronic prostatitis].
Conventional methods of chronic prostatitis treatment aimed at destruction of pathogenic microflora have certain shortcomings. A promising approach is biologic control of prostatic function. A trial was performed of a new drug prostatilen which is a polypeptide isolated from the animal prostate. The study included 307 patients with chronic prostatitis of 4 mon to 36 years duration. Their age ranged from 18 to 74 years. The drug dose of 5-10 mg was administered once a day i.m. for 5-10 days. The immediate effect and long-term one were measured upon the treatment completion and 4-6 months later. A clinical effect manifested following 2-3 injections and grew to maximal values after 5-6 ones. In rare cases the treatment lasted up to 8-10 injections. The drug promoted disappearance or attenuation of the symptoms in 96.7% of the patients. Positive shifts were achieved in pain complaints, diuresis, sexual function, sleep, general condition. The subjective response agreed with objective laboratory and urodynamic evidence. Prostatilen proved effective for chronic prostatitis because it is tolerable, induces no side effects, beneficial in combinations with other modalities in management of this persistent and prone to recurrences disease.
Tkachuk
V N
VN
Gorbachev
A G
AG
Khavinson
V Kh
VKh
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D000075202:Contraindications; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy* / Q000503:physiopathology; D012074:Remission Induction; D014554:Urination / Q000187:drug effects
D010455:Peptides; C053892:cytomedins; C069549:prostatilen
Primenenie prostatilena pri lechenii bol'nykh khronicheskim prostatitom.